AUA 2022: Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies
AUA 2022 oral relugolix for ADT in advanced prostate, specifically a pooled safety analysis from randomized trials.